设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 412|回复: 1

5-氮杂-2’脱氧胞苷处理诱导NY-ESO-1的表达和T淋巴细胞介导的促肿瘤细胞杀伤

[复制链接]
发表于 2015-11-10 23:08:50 | 显示全部楼层 |阅读模式
Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
Background
NY-ESO-1 belongs to the cancer/testis antigen (CTA) family and represents an attractive
target for cancer immunotherapy. Its expression is induced in a variety of solid tumors via dna demethylation of the promoter of CpG islands. However, NY-ESO-1 expression is usually very low or absent in some tumors such as breast cancer or multiple myeloma. Therefore, we established an optimized in vitro treatment protocol for up-regulation of NYESO-1 expression by tumor cells using the hypomethylating agent 5-aza-2'-deoxycytidine(DAC).
Methodology/Principal Findings
We demonstrated de novo induction of NY-ESO-1 in MCF7 breast cancer cells and significantly increased expression in U266 multiple myeloma cells. This effect was time- and dose-dependent with the highest expression of NY-ESO-1 mRNA achieved by the incubation of 10 μM DAC for 72 hours. NY-ESO-1 activation was also confirmed at the protein level as shown by Western blot, flow cytometry, and immunofluorescence staining. The detection and quantification of single NY-ESO-1 peptides presented at the tumor cell surface in the context of HLA-A*0201 molecules revealed an increase of 100% and 50% for MCF7 and U266 cells, respectively. Moreover, the enhanced expression of NY-ESO-1 derived peptides at the cell surface was accompanied by an increased specific lysis of MCF7 and U266 cells by HLA-A*0201/NY-ESO-1(157–165) peptide specific chimeric antigen receptor (CAR) CD8+ T cells. In addition, the killing activity of CAR T cells correlated with the secretion of higher IFN-gamma levels.
Conclusions/Significance
These results indicate that NY-ESO-1 directed immunotherapy with specific CAR T cells
might benefit from concomitant DAC treatment.
5-氮杂-2’脱氧胞苷处理诱导NY-ESO-1的表达和T淋巴细胞介导的促肿瘤细胞杀伤
背景:
NY-ESO-1属于肿瘤、睾丸抗原(CTA)家族,在癌症的免疫治疗中,是一个令人瞩目的靶点。在一些实体肿瘤中,通过CpG岛启动子对DNA的去甲基化,NY-ESO-1的表达被诱导。然而,在某些肿瘤中,如乳腺癌和多发性骨髓瘤中,NY-ESO-1表达很低或者不表达。因此,我们建立了一个优化的体外治疗方案,使用去甲基化剂5-氮杂-2'-脱氧胞苷(DAC,来增加肿瘤细胞NYESO-1的表达上调。
方法/主要的结果:
我们证实了NY-ESO-1会在MCF7乳腺癌细胞中重新诱导的和在U266多发骨髓瘤中表达明显增加。这种效果是时间和剂量依赖的,NY-ESO-1 mRNA会在10μM DAC处理72小时之后表现出最高的表达量。NY-ESO-1的活化也同样由western印迹、流式细胞仪检测、免疫荧光染色在蛋白质水平的监测得以确定。在HLA-A*0201分子中,对癌细胞表面的NY-ESO-1单链多肽进行检测与定量,MCF7和U266 细胞分别显示出了100%50%的增长。此外,细胞表面NY-ESO-1来源多肽的表达增强,伴随着HLA-A*0201/NY-ESO-1(157–165)多肽特异性嵌合抗原(CARCD8+T细胞具有一个增强的特异性溶解MCF7 和 U266细胞的能力。此外,CAR-T细胞的杀伤能力与高水平干扰素的分泌有关。
结论:
这个结果表明,NY-ESO-1指导的CAR-T细胞免疫治疗可能会从同时使用5-氮杂-2’脱氧胞苷(DAC)中受益。

 楼主| 发表于 2015-11-10 23:45:39 | 显示全部楼层
爱康得生物医学技术(苏州)有限公司,专注免疫治疗。
更多资讯,请关注http://www.icartab.com.cn/company_overview.html
您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-2-22 16:40 , Processed in 0.095244 second(s), 19 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表